Management of chemotherapy-associated febrile neutropenia

被引：0
|
作者：
D Cameron
机构：
[1] NCRN Coordinating Centre,
[2] University of Leeds,undefined
[3] MacMillan Wing,undefined
[4] Fairbairn House,undefined
来源：
British Journal of Cancer | 2009年 / 101卷
关键词：
febrile neutropenia; chemotherapy; local protocols; rapid referral; management;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The development of febrile neutropenia during a course of chemotherapy is not only a life-threatening complication, it can also lead to a decision to reduce chemotherapy intensity in subsequent treatment cycles, thus putting patient outcomes at risk. Although there are strategies available for the primary prevention of febrile neutropenia, these are not widely used in the UK management of breast cancer. It is, therefore, paramount to have a well thought out and rigorously implemented care protocol for febrile neutropenia, involving patients, family/carers and health-care professionals in both primary and secondary care, to ensure early detection and effective management.
引用
收藏
页码：S18 / S22
相关论文
共 50 条
  • [1] Management of chemotherapy-associated febrile neutropenia
    Cameron, D.
    [J]. BRITISH JOURNAL OF CANCER, 2009, 101 : S18 - S22
  • [2] Pegfilgrastim prophylaxis in patients at different levels of risk for chemotherapy-associated febrile neutropenia: an observational study
    Fiegl, Michael
    Steger, Guenther G.
    Studnicka, Michael
    Eisterer, Wolfgang
    Jaeger, Christine
    Willenbacher, Wolfgang
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (05) : 505 - 515
  • [3] Circulating biomarkers to predict severe complications in cancer patients with low-risk chemotherapy-associated febrile neutropenia
    Wikstrom Fernandez, S.
    Murillo Herrera, A.
    Garrido Ortega, P.
    de Guadiana-Romualdo, L. Garcia
    Torrella Esteban, P.
    Feliciangeli, E.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1121 - S1121
  • [4] Chemotherapy induced febrile neutropenia: management and prevention
    Marshall, E.
    Innes, H.
    [J]. CLINICAL MEDICINE, 2008, 8 (04) : 448 - 451
  • [5] Pharmacokinetics of Vancomycin among Patients with Chemotherapy-Associated Febrile Neutropenia: Which Would Be the Best Dosing to Obtain Appropriate Exposure?
    Parra Gonzalez, Daniel
    Perez Mesa, Jefferson Alejandro
    Cuervo Maldonado, Sonia Isabel
    Diaz Rojas, Jorge Augusto
    Alberto Cortes, Jorge
    Silva Gomez, Edelberto
    Saavedra Trujillo, Carlos Humberto
    Gomez, Julio
    [J]. ANTIBIOTICS-BASEL, 2022, 11 (11):
  • [6] Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study
    Amy Riedel
    Lan Choe
    John Inciardi
    Courtney Yuen
    Thomas Martin
    B Joseph Guglielmo
    [J]. BMC Infectious Diseases, 7
  • [7] Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study
    Riedel, Amy
    Choe, Lan
    Inciardi, John
    Yuen, Courtney
    Martin, Thomas
    Guglielmo, B. Joseph
    [J]. BMC INFECTIOUS DISEASES, 2007, 7 (1)
  • [8] Prognostic value of procalcitonin and lipopolysaccharide binding protein in cancer patients with chemotherapy-associated febrile neutropenia presenting to an emergency department
    Garcia de Guadiana-Romualdo, Luis
    Cerezuela-Fuentes, Pablo
    Espanol-Morales, Ignacio
    Esteban-Torrella, Patricia
    Jimenez-Santos, Enrique
    Hernando-Holgado, Ana
    Dolores Albaladejo-Oton, Maria
    [J]. BIOCHEMIA MEDICA, 2019, 29 (01) : 57 - 67
  • [9] MANAGEMENT OF FEBRILE EPISODES DURING NEUTROPENIA CAUSED BY CHEMOTHERAPY
    ROLSTON, KVI
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1990, 13 (02): : 171 - 174
  • [10] Chemotherapy induced febrile neutropenia and associated infections: a review
    Camila Thowinson-Hernandez, Maria
    Hernandez-Martinez, Alejandro
    [J]. GACETA MEXICANA DE ONCOLOGIA, 2019, 18 (04): : 333 - 338
12345